5 days FDA Accepts SNY and REGN’s Dupixent Re-Submitted sBLA for UrticariaZacks

The FDA is set to give its decision on SNY and REGN’s sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

11 hours Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge FundsInsider Monkey X